Evaluation of multiple transcriptomic gene risk signatures in male breast cancer
Abstract Male breast cancer (BCa) is a rare disease accounting for less than 1% of all breast cancers and 1% of all cancers in males. The clinical management is largely extrapolated from female BCa. Several multigene assays are increasingly used to guide clinical treatment decisions in female BCa, h...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-07-01
|
Series: | npj Breast Cancer |
Online Access: | https://doi.org/10.1038/s41523-021-00301-0 |
id |
doaj-39b74ac02205476a9300ff36cbb33d6d |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jane Bayani Coralie Poncet Cheryl Crozier Anouk Neven Tammy Piper Carrie Cunningham Monika Sobol Stefan Aebi Kim Benstead Oliver Bogler Lissandra Dal Lago Judith Fraser Florentine Hilbers Ingrid Hedenfalk Larissa Korde Barbro Linderholm John Martens Lavinia Middleton Melissa Murray Catherine Kelly Cecilia Nilsson Monika Nowaczyk Stephanie Peeters Aleksandra Peric Peggy Porter Carolien Schröder Isabel T. Rubio Kathryn J. Ruddy Christi van Asperen Danielle Van Den Weyngaert Carolien van Deurzen Elise van Leeuwen-Stok Joanna Vermeij Eric Winer Sharon H. Giordano Fatima Cardoso John M. S. Bartlett |
spellingShingle |
Jane Bayani Coralie Poncet Cheryl Crozier Anouk Neven Tammy Piper Carrie Cunningham Monika Sobol Stefan Aebi Kim Benstead Oliver Bogler Lissandra Dal Lago Judith Fraser Florentine Hilbers Ingrid Hedenfalk Larissa Korde Barbro Linderholm John Martens Lavinia Middleton Melissa Murray Catherine Kelly Cecilia Nilsson Monika Nowaczyk Stephanie Peeters Aleksandra Peric Peggy Porter Carolien Schröder Isabel T. Rubio Kathryn J. Ruddy Christi van Asperen Danielle Van Den Weyngaert Carolien van Deurzen Elise van Leeuwen-Stok Joanna Vermeij Eric Winer Sharon H. Giordano Fatima Cardoso John M. S. Bartlett Evaluation of multiple transcriptomic gene risk signatures in male breast cancer npj Breast Cancer |
author_facet |
Jane Bayani Coralie Poncet Cheryl Crozier Anouk Neven Tammy Piper Carrie Cunningham Monika Sobol Stefan Aebi Kim Benstead Oliver Bogler Lissandra Dal Lago Judith Fraser Florentine Hilbers Ingrid Hedenfalk Larissa Korde Barbro Linderholm John Martens Lavinia Middleton Melissa Murray Catherine Kelly Cecilia Nilsson Monika Nowaczyk Stephanie Peeters Aleksandra Peric Peggy Porter Carolien Schröder Isabel T. Rubio Kathryn J. Ruddy Christi van Asperen Danielle Van Den Weyngaert Carolien van Deurzen Elise van Leeuwen-Stok Joanna Vermeij Eric Winer Sharon H. Giordano Fatima Cardoso John M. S. Bartlett |
author_sort |
Jane Bayani |
title |
Evaluation of multiple transcriptomic gene risk signatures in male breast cancer |
title_short |
Evaluation of multiple transcriptomic gene risk signatures in male breast cancer |
title_full |
Evaluation of multiple transcriptomic gene risk signatures in male breast cancer |
title_fullStr |
Evaluation of multiple transcriptomic gene risk signatures in male breast cancer |
title_full_unstemmed |
Evaluation of multiple transcriptomic gene risk signatures in male breast cancer |
title_sort |
evaluation of multiple transcriptomic gene risk signatures in male breast cancer |
publisher |
Nature Publishing Group |
series |
npj Breast Cancer |
issn |
2374-4677 |
publishDate |
2021-07-01 |
description |
Abstract Male breast cancer (BCa) is a rare disease accounting for less than 1% of all breast cancers and 1% of all cancers in males. The clinical management is largely extrapolated from female BCa. Several multigene assays are increasingly used to guide clinical treatment decisions in female BCa, however, there are limited data on the utility of these tests in male BCa. Here we present the gene expression results of 381 M0, ER+ve, HER2-ve male BCa patients enrolled in the Part 1 (retrospective analysis) of the International Male Breast Cancer Program. Using a custom NanoString™ panel comprised of the genes from the commercial risk tests Prosigna®, OncotypeDX®, and MammaPrint®, risk scores and intrinsic subtyping data were generated to recapitulate the commercial tests as described by us previously. We also examined the prognostic value of other risk scores such as the Genomic Grade Index (GGI), IHC4-mRNA and our prognostic 95-gene signature. In this sample set of male BCa, we demonstrated prognostic utility on univariate analysis. Across all signatures, patients whose samples were identified as low-risk experienced better outcomes than intermediate-risk, with those classed as high risk experiencing the poorest outcomes. As seen with female BCa, the concordance between tests was poor, with C-index values ranging from 40.3% to 78.2% and Kappa values ranging from 0.17 to 0.58. To our knowledge, this is the largest study of male breast cancers assayed to generate risk scores of the current commercial and academic risk tests demonstrating comparable clinical utility to female BCa. |
url |
https://doi.org/10.1038/s41523-021-00301-0 |
work_keys_str_mv |
AT janebayani evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT coralieponcet evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT cherylcrozier evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT anoukneven evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT tammypiper evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT carriecunningham evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT monikasobol evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT stefanaebi evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT kimbenstead evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT oliverbogler evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT lissandradallago evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT judithfraser evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT florentinehilbers evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT ingridhedenfalk evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT larissakorde evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT barbrolinderholm evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT johnmartens evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT laviniamiddleton evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT melissamurray evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT catherinekelly evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT cecilianilsson evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT monikanowaczyk evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT stephaniepeeters evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT aleksandraperic evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT peggyporter evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT carolienschroder evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT isabeltrubio evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT kathrynjruddy evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT christivanasperen evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT daniellevandenweyngaert evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT carolienvandeurzen evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT elisevanleeuwenstok evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT joannavermeij evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT ericwiner evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT sharonhgiordano evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT fatimacardoso evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer AT johnmsbartlett evaluationofmultipletranscriptomicgenerisksignaturesinmalebreastcancer |
_version_ |
1721245759909658624 |
spelling |
doaj-39b74ac02205476a9300ff36cbb33d6d2021-08-01T11:34:48ZengNature Publishing Groupnpj Breast Cancer2374-46772021-07-01711810.1038/s41523-021-00301-0Evaluation of multiple transcriptomic gene risk signatures in male breast cancerJane Bayani0Coralie Poncet1Cheryl Crozier2Anouk Neven3Tammy Piper4Carrie Cunningham5Monika Sobol6Stefan Aebi7Kim Benstead8Oliver Bogler9Lissandra Dal Lago10Judith Fraser11Florentine Hilbers12Ingrid Hedenfalk13Larissa Korde14Barbro Linderholm15John Martens16Lavinia Middleton17Melissa Murray18Catherine Kelly19Cecilia Nilsson20Monika Nowaczyk21Stephanie Peeters22Aleksandra Peric23Peggy Porter24Carolien Schröder25Isabel T. Rubio26Kathryn J. Ruddy27Christi van Asperen28Danielle Van Den Weyngaert29Carolien van Deurzen30Elise van Leeuwen-Stok31Joanna Vermeij32Eric Winer33Sharon H. Giordano34Fatima Cardoso35John M. S. Bartlett36Ontario Institute for Cancer ResearchDepartment of Statistics, European Organization for Research and Treatment of Cancer (EORTC) HeadquartersOntario Institute for Cancer ResearchDepartment of Statistics, European Organization for Research and Treatment of Cancer (EORTC) HeadquartersUniversity of EdinburghUniversity of EdinburghUniversity of EdinburghSwiss Group for Clinical Cancer Research (SAKK)Department of Oncology, Cheltenham General HospitalGlobal Academic Programs, University of Texas MD Anderson Cancer CenterDepartment of Medical Oncology, Jules Bordet InstituteBeatson West of Scotland Cancer CentreBreast International GroupDivision of Oncology, Department of Clinical Sciences, Lund UniversityUniversity of WashingtonDepartment of Oncology, Sahlgrenska University HospitalMedical Oncology, Erasmus Medical Center Rotterdam; BOOGDepartment Pathology, University of Texas MD Anderson Cancer CenterDepartment of Pathology, Memorial Sloan Kettering Cancer CenterAll Ireland Cooperative Oncology Research Group (ICORG)Department of Oncology, Västmanlands HospitalSpecialist Hospital. St. WojciechDepartment of Radiation Oncology MaastroDepartment of Statistics, European Organization for Research and Treatment of Cancer (EORTC) HeadquartersDivisions of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center & Department of Pathology, University of WashingtonDepartment Medical Oncology, University Medical Center Groningen; BOOGBreast Surgical Unit. Hospital Universitario Vall d´HebronMayo Clinic, Department of OncologyDepartment of Clinical Genetics, Leiden University Medical Center; BOOGDepartment of Radiotherapy, ZNA MiddelheimDepartment Pathology, Erasmus Medical Center; BOOGDutch Breast Cancer Research Group (BOOG)Department of Medical Oncology, ZNA Jan PalfijnDana-Farber Cancer InstituteUniversity of Texas MD Anderson Cancer CenterBreast Unit, Champalimaud Clinical Center/Champalimaud Foundation; EORTCOntario Institute for Cancer ResearchAbstract Male breast cancer (BCa) is a rare disease accounting for less than 1% of all breast cancers and 1% of all cancers in males. The clinical management is largely extrapolated from female BCa. Several multigene assays are increasingly used to guide clinical treatment decisions in female BCa, however, there are limited data on the utility of these tests in male BCa. Here we present the gene expression results of 381 M0, ER+ve, HER2-ve male BCa patients enrolled in the Part 1 (retrospective analysis) of the International Male Breast Cancer Program. Using a custom NanoString™ panel comprised of the genes from the commercial risk tests Prosigna®, OncotypeDX®, and MammaPrint®, risk scores and intrinsic subtyping data were generated to recapitulate the commercial tests as described by us previously. We also examined the prognostic value of other risk scores such as the Genomic Grade Index (GGI), IHC4-mRNA and our prognostic 95-gene signature. In this sample set of male BCa, we demonstrated prognostic utility on univariate analysis. Across all signatures, patients whose samples were identified as low-risk experienced better outcomes than intermediate-risk, with those classed as high risk experiencing the poorest outcomes. As seen with female BCa, the concordance between tests was poor, with C-index values ranging from 40.3% to 78.2% and Kappa values ranging from 0.17 to 0.58. To our knowledge, this is the largest study of male breast cancers assayed to generate risk scores of the current commercial and academic risk tests demonstrating comparable clinical utility to female BCa.https://doi.org/10.1038/s41523-021-00301-0 |